Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Phase 2 Active not recruiting 62 enrolled Sun Yat-sen University

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase II, single-arm clinical study designed to evaluate the efficacy and safety of Ipromlimab combined with Tuvonralimab, plus Albumin-Bound Paclitaxel and Nedaplatin, as neoadjuvant therapy for patients with locally advanced resectable esophageal squamous cell carcinoma.

Timeline

Start: 2025-12-17
Primary completion: 2029-06-20
Completion: 2029-12-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ipromlimab	Unknown	5 mg/kg	Intravenous
Subject	Nedaplatin	Small molecule	75 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	260 mg/m2	Intravenous
Subject	Tuvonralimab	Monoclonal antibody	5 mg/kg	Intravenous

Indications

No indication recorded.